Abstract:Olfactory receptor 1393 (Olfr1393) is a G‐protein coupled receptor ectopically expressed in the murine kidney and liver that has functionality in glucose reabsorption via the sodium‐glucose linked‐transporters (Sglts). Due to the recent therapeutic advances regarding inhibition of the Sglts for both type 1 (T1D) and type 2 (T2D) diabetes, we sought to elucidate the contribution of Olfr1393 to the development and progression of the disease. Previously, we determined that Olfr1393 knockout (KO) mice exhibit improved glucose tolerance and attenuated glomerular hyperfiltration when challenged with a high fat diet (60% kcal from fat) to induce early stages of T2D as compared to their wildtype (WT) counterparts. This was linked to the reduced expression of SGLT2 within the proximal tubule of the KO mice. To determine if Olfr1393 is also involved in T1D, both KO and WT mice were challenged with low‐dose injections of Streptozotocin (STZ; 55 mg/kg BW) or vehicle control (PBS; 55 mg/kg BW) for 5 days to induce depletion of pancreatic β cells. In as little as 2 weeks, both KO and WT male STZ‐treated mice presented with hyperglycemia (2hr fasting blood glucose; WT STZ ‐ 433 ± 32.6 mg/dL, KO STZ ‐ 309 ± 22.6 mg/dL, WT V ‐ 169.7 ± 7.96 mg/dL, KO V ‐ 169.6 ± 10.9 mg/dL), although this hyperglycemia was significantly attenuated in KO mice (p < 0.005). At five weeks, this change was even more pronounced with a significant improvement in hyperglycemia noted even after an overnight fast (WT STZ ‐ 473 ± 28.35 mg/dL, KO STZ ‐ 300 ± 36.24 mg/dL). This improved phenotype is not a result of decreased sensitivity to STZ as islet cell area is similar between STZ‐treated KOs and WTs (WT STZ ‐ 4218 ± 826.5 um2, KO STZ ‐ 4913 ± 2335 um2). The improvement in blood glucose levels also correlated with a significant improvement in glucose tolerance noted in the diabetic KO mice (AUC: WT STZ ‐ 35471 ± 3279, KO STZ ‐ 2868 ± 2118; p<0.01). Notably, all improvement was seen in the male mice as STZ induced a sex dependent phenotype of T1D with female mice found to be resistant to the development of hyperglycemia (2hr fasting blood glucose; WT STZ ‐ 167.7 ± 29.16 mg/dL, KO STZ ‐ 178.0 ± 31.92 mg/dL, WT V ‐ 131.0 ± 38.59 mg/dL, KO V ‐ 144.4 ± 15.92 mg/dL). Contrary to data obtained in our T2D model, neither diabetic WT nor KO mice presented with the commonly noted diabetes‐induced hyperfiltration as measured by transdermal clearance of FITC‐sinistrin; this tracked with a lack of an alteration in glomerular area or morphology as assessed by PAS histological analysis. Additionally, we did not detect any changes in plasma electrolytes (iSTAT Chem8+) or blood pressure (via tail cuff BP‐2000 Blood Pressure Analysis System). Given the improved diabetic phenotype, efforts are currently underway to determine if loss of Olfr1393 leads to changes in the expression or localization of renal SGLT1 and/or SGLT2 in the setting of T1D. Collectively, our data has uncovered a novel regulator of glucose handling, and sheds light on how the modulation of this pathway influences the development of diabetes. NIDDK

Characterizing Murine Diabetic Glucose Metabolism Under Conditions of Attenuated Renal Glucose Reabsorption

Elucidating the Mechanism for Renal Olfactory Receptor 1393’s Attenuated Type 1 Diabetic Phenotype

Effects of SGLT2 Ablation or Inhibition on Corticosterone Secretion in High-Fat-Fed Mice: Exploring a Nexus with Cytokine Levels

OR24-6 Liver-Specific Inhibition of Sialic Acid Biosynthesis Improves Systemic Glucose Homeostasis in Mice

Sodium-Glucose Co-Transporter (sglt) and Glucose Transporter (glut) Expression in the Kidney of Type 2 Diabetic Subjects

PS-BPB06-1: GLOMERULAR HEMODYNAMIC CHANGES WITH SGLT2 INHIBITION IN TYPE 2 DIABETIC RATS USING IN VIVO IMAGING

SGLT1 Inhibition Attenuates Apoptosis in Diabetic Cardiomyopathy Via the JNK and P38 Pathway

Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice

Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice

SGLT2 knockdown restores the Th17/Treg balance and suppresses diabetic nephropathy in db/db mice by regulating SGK1 via Na +

Sodium–glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice

Renal olfactory receptor 1393 contributes to the progression of type 2 diabetes in a diet-induced obesity model

1656-P: In Vivo Downregulation of Transglutaminase 2 in High Fat Diet (HFD)-Induced Obese Mice Reduces Metabolic Syndrome–Associated Factors

SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function

The Molecular Effects of SGLT2i Empagliflozin on the Autophagy Pathway in Diabetes Mellitus Type 2 and Its Complications

Comparative RNA-Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease

A High-Fat Diet Catalyzes Progression to Hyperglycemia in Mice with Selective Impairment of Insulin Action in Glut4-expressing Tissues.

Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice

Restoring Glucose Balance: Conditional HMGB1 Knockdown Mitigates Hyperglycemia in a Streptozotocin Induced Mouse Model

SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease

The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice